Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin

2004/03/01 by Andrew L. Lovering, Jon P. Ride, Christopher M. Bunce +3 · 26 citations
Biochemistry, Genetics and Molecular Biology · #Aldose Reductase and Taurine #Heme Oxygenase-1 and Carbon Monoxide #Eicosanoids and Hypertension Pharmacology

paper · doi:10.1158/0008-5472.can-03-2847

Abstract

It is becoming increasingly well established that nonsteroidal anti-inflammatory drugs (NSAID) protect against tumors of the gastrointestinal tract and that they may also protect against a variety of other tumors. These activities have been widely attributed to the inhibition of cylooxygenases (COX) and, in particular, COX-2. However, several observations have indicated that other targets may be involved. Besides targeting COX, certain NSAID also inhibit enzymes belonging to the aldo-keto reductase (AKR) family, including AKR1C3. We have demonstrated previously that overexpression of AKR1C3 acts to suppress cell differentiation and promote proliferation in myeloid cells. However, this enzyme has a broad tissue distribution and therefore represents a novel candidate for the target of the COX-independent antineoplastic actions of NSAID. Here we report on the X-ray crystal structures of AKR1C3 complexed with the NSAID indomethacin (1.8 A resolution) or flufenamic acid (1.7 A resolution). One molecule of indomethacin is bound in the active site, whereas flufenamic acid binds to both the active site and the beta-hairpin loop, at the opposite end of the central beta-barrel. Two other crystal structures (1.20 and 2.1 A resolution) show acetate bound in the active site occupying the proposed oxyanion hole. The data underline AKR1C3 as a COX-independent target for NSAID and will provide a structural basis for the future development of new cancer therapies with reduced COX-dependent side effects.

Cited by

• AKR1C Isoforms Represent a Novel Cellular Target for Jasmonates alongside Their Mitochondrial-Mediated Effects
• An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. [europepmc]
• Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. [europepmc]
• Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers. [europepmc]
• Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. [europepmc]
• Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1). [europepmc]
• Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). [europepmc]
• Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. [europepmc]
• Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily. [europepmc]
• Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. [europepmc]
• Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling. [europepmc]
• Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. [europepmc]
• Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. [europepmc]
• AKR1C3 as a target in castrate resistant prostate cancer. [europepmc]
• Anthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular-bond shifted hydrogen. [europepmc]
• Androgen biosynthesis in castration-resistant prostate cancer. [europepmc]
• Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities. [europepmc]
• The Recognition of Identical Ligands by Unrelated Proteins. [europepmc]
• Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. [europepmc]
• Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. [europepmc]
• Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. [europepmc]
• Inverse Molecular Docking as a Novel Approach to Study Anticarcinogenic and Anti-Neuroinflammatory Effects of Curcumin. [europepmc]
• The role of adrenal derived androgens in castration resistant prostate cancer. [europepmc]
• Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. [europepmc]
• Variability of the Genes Involved in the Cellular Redox Status and Their Implication in Drug Hypersensitivity Reactions. [europepmc]
• Prophylaxis of posterior capsule opacification through autophagy activation with indomethacin-eluting intraocular lens. [europepmc]

Related

• Polynomial Bounds in Koldobsky's Discrete Slicing Problem
• On the "second" Kahn--Kalai Conjecture
• The generalized Kurepa hypothesis at singular cardinals
• The zero blocking numbers of generalized Kneser graphs and generalized Johnson graphs
• Fractional Clique Decompositions of Dense Hypergraphs